Acusphere AI-700 Imaging Agent Phase III Protocols Expected By Early 2002
Executive Summary
Acusphere plans to submit Phase III protocols for its ultrasound contrast agent AI-700 to FDA by early 2002.
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS038457
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS038457
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.